Mesothelioma
Types
Pleural Mesothelioma
Peritoneal Mesothelioma
Mesothelioma glossary
Asbestos Imports
|
Prospective trial for the treatment
of malignant peritoneal mesothelioma
SOURCE: Am Surg 2001 Oct;67(10):999-1003
Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR, Levine
EA.
Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina,
USA.
Malignant peritoneal mesothelioma (MPM) is a rare and often rapidly
fatal disease with median survival of 5 to 12 months for untreated cases
and 16 months reported after multimodality treatment. We report a prospective
clinical treatment study using cytoreductive surgery combined with intraoperative
intraperitoneal heated chemotherapy (IPHC) perfusion using mitomycin C
for MPM. Twelve patients (11 male with a mean age 51 years) were treated.
Seven patients presented with bulky disease and seven with ascites. All
underwent exploratory laparotomy with histologically confirmed diagnosis
of MPM. Surgical debulking as feasible was performed. Complete gross tumor
removal was possible in only one patient. Cytoreduction was followed by
a 2-hour closed low-volume IPHC using mitomycin C. One patient died 50
days postoperatively from complications relating to small bowel perforation.
Hematologic toxicity of the procedure was minimal. Ascites was controlled
in all patients and permanently in 86 per cent of patients presenting
with ascites. To date median survival is 34.2 months with median follow-up
of 45.2 months. One patient was re-explored for ventral hernia 2 years
post-IPHC, had negative peritoneal biopsies, and remains disease-free
at 5 years. Given the dismal prognosis associated with MPM the results
of treatment with cytoreductive surgery combined with IPHC perfusion are
encouraging. The rarity of MPM makes appropriately powered prospective
randomized trials unlikely. Therefore, we now offer this approach off
protocol; however, further study of this combined modality therapy is
warranted.
To receive a FREE information packet, please fill out the following form (U.S. only please):
| Pleural Mesothelioma | Peritoneal Mesothelioma | Home | Pathogenesis | Genetic
susceptibility and asbestos exposure | Asbestos
Imports | |